Open AccessThe Plasma Concentration of Medroxyprogesterone Acetate and Ovarian Function During Treatment with Medroxyprogesterone Acetate in 5 and 10 mg Doses
Author(s) -
Wikström Agneta,
Green Britt,
Johansson Elof D. B.
Publication year - 1984
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016348409154654
Subject(s) - medroxyprogesterone acetate , ovulation , medicine , medroxyprogesterone , luteal phase , radioimmunoassay , endocrinology , megestrol acetate , population , estrogen , hormone , cancer , environmental health
. Peripheral plasma levels of medroxyprogesterone acetate (MPA) were determined by radioimmunoassay in 5 women after oral administration of 5 and 10 mg medroxyprogesterone acetate daily. Peak levels of MPA in plasma were recorded within 1‐3 hours of taking the tablet, which indicates a rapid absorption from the gastro‐intestinal tract. The levels of medroxyprogesterone acetate 12 hours after taking of the 5 mg tablet‐remained constant throughout the 8 weeks of study. Peripheral plasma levels of estradiol and progesterone were determined throughout treatment. The estradiol levels indicated development of follicles in 7 out of 10 treatment months in the 5 mg group, and in 3 of the subjects treated with 10 mg MPA. The progesterone levels in those women treated with 5 mg MPA showed normal luteal concentration values in 2 out of 10 treatment months. No woman treated with 10 mg MPA had an increase in progesterone during the 21‐day period of treatment. The results obtained in this study suggest that 10 mg MPA daily will inhibit ovulation but 5 mg is not sufficient to inhibit ovulation in all women.